- Home
- Find medicine
- Human medicines
About
The marketing authorisation for Vibativ has been suspended at the recommendation of the Agency’s Committee for Medicinal Products for Human Use (CHMP).
| Name | Language | First published | Last updated |
|---|---|---|---|
| Vibativ : EPAR - Summary for the public | BG = bălgarski | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | ES = español | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | CS = čeština | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | DA = dansk | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | DE = Deutsch | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | ET = eesti keel | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | EL = elliniká | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | EN = English | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | FR = français | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | IT = italiano | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | LV = latviešu valoda | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | LT = lietuvių kalba | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | HU = magyar | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | MT = Malti | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | NL = Nederlands | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | PL = polski | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | PT = português | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | RO = română | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | SK = slovenčina | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | SL = slovenščina | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | FI = suomi | 29/09/2011 | 22/08/2012 |
| Vibativ : EPAR - Summary for the public | SV = svenska | 29/09/2011 | 22/08/2012 |
This EPAR was last updated on 18/04/2013 .
More detail is available in the summary of product characteristics
Authorisation details
Product information
Product information
08/02/2013 Vibativ -EMEA/H/C/001240 -T/0004
| Name | Language | First published | Last updated |
|---|---|---|---|
| Vibativ : EPAR - Product Information | BG = bălgarski | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | ES = español | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | CS = čeština | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | DA = dansk | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | DE = Deutsch | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | ET = eesti keel | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | EL = elliniká | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | EN = English | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | FR = français | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | IT = italiano | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | LV = latviešu valoda | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | LT = lietuvių kalba | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | HU = magyar | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | MT = Malti | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | NL = Nederlands | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | PL = polski | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | PT = português | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | RO = română | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | SK = slovenčina | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | SL = slovenščina | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | FI = suomi | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | SV = svenska | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | IS = Islenska | 29/09/2011 | 18/04/2013 |
| Vibativ : EPAR - Product Information | NO = Norsk | 29/09/2011 | 18/04/2013 |
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Antibacterials for systemic use
Therapeutic indication
Vibativ is indicated for the treatment of adults with nosocomial pneumonia including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA).
Vibativ should be used only in situations where it is known or suspected that other alternatives are not suitable (see sections 4.3, 4.4, 4.8 and 5.1).
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Assessment History
Changes since initial authorisation of medicine
| Name | Language | First published | Last updated |
|---|---|---|---|
| Vibativ : EPAR - Procedural steps taken and scientific information after authorisation | (English only) | 22/08/2012 | 18/04/2013 |
| Vibativ-H-C-1240-A20-01 : EPAR - Assessment Report - Article 20 | (English only) | 22/08/2012 |
Initial marketing-authorisation documents
| Name | Language | First published | Last updated |
|---|---|---|---|
| Vibativ : EPAR - Public assessment report | (English only) | 29/09/2011 | 22/08/2012 |
| CHMP summary of positive opinion for Vibativ | (English only) | 20/05/2011 | 22/08/2012 |
Suspended
This medicine is currently suspended for use in the European Union
Patient safety
News
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012 (17/02/2012)
- European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories (16/02/2012)
- European Medicines Agency recommends precautionary recall of remaining batch of Vistide manufactured at Ben Venue Laboratories (13/12/2011)
- European Medicines Agency gives further interim recommendations on dealing with shortcomings in quality assurance at Ben Venue Laboratories (09/12/2011)
- European Medicines Agency gives interim recommendations to deal with shortcomings in quality assurance at Ben Venue Laboratories (22/11/2011)
